Summing up data discussed at the ecancer CDK symposium at the St Gallen 2017 conference, Dr Giuseppe Curigliano (European Institute of Oncology, Milan, Italy), Dr Carmen Criscitiello (European Institute of Oncology, Milan, Italy), Dr Ghadeer Shubassi (Toronto, Canada) and Prof Pierfranco Conte - Istituto Oncologico Veneto, Padova, Italy) begin with a review of the MONALEESA trial program of ribociclib.
In the PALOMA trials, Dr Criscitiello describes the successes of palbociclib of treating patients sensitive and resistant to endocrine therapy.
Considering the therapeutic and financial value of establishing a prognostic biomarker, Dr Shubassi looks to substrates in the endocrine pathway that may prove useful, though none has yet been established.
Prof Conte highlights that, for patients best suited to endocrine therapy, CDK therapy may be suitable in a second line setting, but that a number of long-term questions about CDK suitability remain unanswered.
Discussion then turns to the significance of progression-free survival as a trial endpoint in comparison to overall survival, which requires data gathered over a time-scale not yet reached in any trial of CDK inhibition.
MONALEESA2 and PALOMA 2 was previously contrasted by Dr Michael Gnant at ESMO 2016.
Dr Alison Jones spoke at an ecancer CDK symposium at EONS 10 about how best to manage side effects associated with CDK inhibitors.
For more on the cellular mechanisms of CDK inhibition and ongoing trials, a webcast of the ecancer ESMO 2016 CDK symposium is available here.
Supported by a grant from Pfizer Inc.